Clinical trials
Breast Cancer Risk clinical trials
Below are recruiting breast cancer risk clinical trials, each written for real people, not researchers. We’re tracking 740 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06891651Recruiting
21-gene testing for older breast cancer patients with lymph node spread
This trial looks at using a 21-gene test to guide treatment decisions for women aged 65 or older who have breast cancer that has spread to lymph nodes. It aims to see if this test can help avoid unnecessary chemotherapy in this group.
Jinan, ShandongAges 65 years+ - NCT07264790RecruitingPhase 1
Minoxidil for Better Blood Flow in Breast Reconstruction
This trial tests whether applying minoxidil (a hair growth medication) to breast tissue during surgery can improve blood flow to the reconstructed breast. It is for women who are having both breasts removed to prevent cancer and have reconstruction on the same day.
Durham, North CarolinaAges 18 years+ - NCT07251868Recruiting
Study of SG in breast cancer with brain metastases
This study follows patients with breast cancer that has spread to the brain and who have already received the drug Sacituzumab Govitecan (SG). The goal is to learn how well SG works in real-world settings and to see how patients are doing over time.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07242352RecruitingPhase 3
Comparing elacestrant to standard hormone therapy for high-risk early breast cancer
This trial tests a new hormone therapy drug called elacestrant against standard hormone treatments for people with a specific type of early breast cancer (ER+/HER2-) that has a high chance of coming back. The goal is to see if elacestrant works better at keeping the cancer from returning.
Mannheim, Baden-WurttembergAges 18 years+ - NCT07237256RecruitingPhase 3
Testing less chemo for HR+ HER2- breast cancer with ribociclib
This trial tests whether some people with hormone receptor-positive, HER2-negative early breast cancer can safely receive less chemotherapy when also taking the targeted drug ribociclib after surgery. You may qualify if you have a specific stage of breast cancer and are planning to take hormone therapy for at least 5 years.
AmiensAges 18 years+ - NCT07225309Recruiting
Meaning-Centered Therapy for Mexican Adults with Advanced Cancer
This study tests a therapy program called Meaning-Centered Therapy designed to help adults in Mexico with advanced cancer find meaning and improve their well-being. It involves sessions delivered by trained providers at the National Cancer Institute in Mexico (INCan).
New York, New YorkAges 18 years+ - NCT07222215RecruitingPhase 2
Capacitabine with or without elacestrant for ER+ breast cancer
This trial tests if adding a new oral targeted therapy (elacestrant) to standard chemotherapy (capecitabine) works better than chemotherapy alone for people with a specific type of advanced breast cancer that is hormone-sensitive (ER-positive) and has stopped responding to hormone therapy.
Boston, MassachusettsAges 18 years+ - NCT05013255RecruitingPhase 2
Pioglitazone to treat fatigue in hormone-positive breast cancer
This Phase 2 study tests whether pioglitazone can reduce fatigue in people with certain types of breast cancer. You may be eligible if your cancer is estrogen- and progesterone-positive (ER+/PR+) and you plan surgery soon.
Morgantown, West VirginiaAges 18 years+ - NCT07218432Recruiting
TheraBionic device study for hormone-positive breast cancer
This trial tests a device called TheraBionic P1, which uses low-level radiofrequency energy, for women with early-stage hormone receptor-positive, HER2-negative breast cancer. It is given before surgery to see if it can help shrink the tumor.
Clarkston, MichiganAges 22 years+ - NCT07205822RecruitingPhase 3
Dato-DXd for advanced HR-positive, HER2-low breast cancer
This trial tests a new drug called Dato-DXd for people with a certain type of advanced breast cancer that has stopped responding to hormone therapy. The drug targets a protein on cancer cells to help stop the cancer from growing.
Largo, FloridaAges 18 years+ - NCT07207070RecruitingPhase 3
New drug combination for PIK3CA-mutated breast cancer
This trial tests a new combination of two drugs (JS105 plus dalpiciclib and fulvestrant) against a standard combination (dalpiciclib plus fulvestrant) for people whose breast cancer has a PIK3CA mutation. The goal is to see if adding JS105 helps control the cancer longer.
Beijing, Beijing MunicipalityAges 18–75 - NCT07206121Recruiting
Study of a new device for breast cancer surgery
This trial tests a device that uses radiofrequency energy to help remove breast cancer during surgery. It may be an option for women over 50 with a specific type of early-stage breast cancer.
Galveston, TexasAges 50 years+ - NCT07211178Recruiting
Tracking cancer DNA in blood to detect early return of breast cancer
This study tracks tiny traces of cancer DNA in the blood over time to see if it can find early signs of breast cancer coming back. It looks at different types of breast cancer and at different points in a patient's treatment journey.
Birmingham, AlabamaAges 18–99 - NCT07207564Recruiting
Improving breast cancer risk with pathology, radiology, and genetics
This study looks at tissue, imaging, and genetic information from women who had a non-cancerous breast biopsy to better understand breast cancer risk. It may help improve how we predict and prevent breast cancer in the future.
Jacksonville, FloridaAges 18–100 - NCT05288777RecruitingPhase 2/Phase 3
Testing follow-up chemo and radiation for high-risk breast cancer
This trial studies a standard follow-up treatment plan that combines chemotherapy and radiation after surgery, and it looks for blood/tissue “biomarkers” that predict who benefits most. If you have high-risk breast cancer that didn’t fully disappear after initial (neoadjuvant) chemo, you may be eligible to help guide better future treatment choices.
Charlottesville, VirginiaAges 18 years+ - NCT07198724RecruitingPhase 1/Phase 2
A study of elacestrant plus Enhertu for advanced breast cancer
This trial tests a new combination of two targeted drugs (elacestrant and Enhertu) for people with a specific type of advanced breast cancer (HR-positive, HER2-low or ultra-low) that did not respond to standard treatments like CDK4/6 inhibitors. The goal is to see if this combination works better than current options.
Boston, MassachusettsAges 18 years+ - NCT07195227RecruitingPhase 2
Camizestrant plus ribociclib for advanced breast cancer
This trial tests a combination of two drugs, camizestrant and ribociclib, for people with a certain type of advanced breast cancer (HR+/HER2-). It is for those whose cancer has grown or spread despite previous hormone therapy. The goal is to see if this new combination can help control the cancer.
DessauAges 18 years+ - NCT07193394RecruitingPhase 2
Tucatinib and trastuzumab for HER3-mutant breast cancer
This trial tests a combination of two targeted drugs (tucatinib and trastuzumab) for people with a specific gene change (HER3 mutation) in advanced breast cancer that has spread or cannot be removed by surgery. It may be an option if you have already had at least two previous treatments.
BordeauxAges 18 years+ - NCT07191717RecruitingPhase 2
Imlunestrant and abemaciclib for early ER+ breast cancer
This trial tests whether adding two targeted drugs, imlunestrant and abemaciclib, to your usual hormone therapy can lower the chance of your breast cancer coming back. It is for people with early-stage ER+ breast cancer who have no signs of cancer on scans but have tiny amounts of tumor DNA in their blood (called ctDNA).
Los Angeles, CaliforniaAges 18 years+ - NCT07179744Recruiting
Skipping radiation for low-risk node-positive breast cancer
This trial tests whether some women with low-risk breast cancer that has spread to a few lymph nodes can safely skip radiation therapy after surgery. It aims to reduce side effects while keeping the cancer from coming back.
Guangzhou, GuangdongAges 18–70 - NCT06207734RecruitingPhase 2
Stopping CDK4/6 inhibitors in advanced breast cancer
This trial looks at what happens when women with advanced hormone-positive, HER2-negative breast cancer stop taking a CDK4/6 inhibitor after at least a year of successful treatment. The goal is to see if it's safe to take a break from the CDK4/6 inhibitor while continuing hormone therapy alone.
BerlinAges 18 years+ - NCT05658172Recruiting
Less vs more frequent follow-up after early breast cancer
This trial compares standard follow-up visits versus more intensive follow-up for people with early breast cancer after their main treatment. The goal is to see whether closer monitoring finds problems earlier or improves outcomes.
UlmAges 18–75 - NCT07159451RecruitingPhase 2
Elacestrant for premenopausal women with early breast cancer
This trial tests a new hormone therapy pill, elacestrant, given alone or with another drug to suppress ovarian function before surgery. It's for premenopausal women with early-stage, hormone receptor-positive, HER2-negative breast cancer to see if it can shrink the tumor.
VillejuifAges 18 years+ - NCT07150208RecruitingPhase 2
T-DXd with or without Avastin for HER2-low breast cancer that spread to the brain
This trial tests a combination of two targeted drugs (T-DXd and bevacizumab) for people with HER2-low breast cancer that has spread to the brain. It aims to see if adding bevacizumab helps the main drug work better against brain metastases.
ShanghaiAges 18–70
Hear when a new Breast Cancer Risk trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast cancer risk?
- Yes. Clin2 currently lists 740 recruiting breast cancer risk studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast cancer risk trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast cancer risk trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.